跳到主要内容

新闻与日历

新闻: 截至 2026-10-06
这些标记是什么意思

重要性是模型对已发布报道给出的 1–5 分,不是对市场的预测。

已排定事件行上的影响是公司显著度层级(高/中由图谱中心度与规模判定;低仅用于人工整理的次要事件),不是对波动幅度的预测。

标记为已确认的财报日期,是 Yahoo Finance 认定由公司确认的;预估表示尚未公布。未加标记的行没有可查的出处记录。

经济数据发布属于宏观、不归属任何产业,因此在任何视图下都会保留。没有数值的发布表示尚未公布,页面会直说,而不是显示为零。

涵盖被追踪公司的即将到来的事件;已过去的事件会归档,并在可得时补上结果——这些结果都经人工整理并附引用,绝不杜撰。没有结果的历史行会显示“结果待定”。

解禁或指数调整的行会多出一行算术——将变得可卖出的股数,或指数基金必须买入的股数,以占流通股的比例表示——依据招股说明书或指数编制方法读出,两个数字都在该行注明出处。它陈述的是机制,不是价格走势。由 IPO + 180 天推算出的解禁日期会一直标为预估,直到公司自己说明为止。

未来

已排定 · 今天与明天 · 日历更新于 2026-10-12

10月12日周一 · 今天

10月13日周二

过往

已发布 · 最新在前

8月28日周五

监管

14:53
Yahoo Finance

AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn's Disease

AbbVie has applied for European Union authorisation of a subcutaneous formulation of Skyrizi in Crohn's disease.

大盘 打开原文 ↗

产品

14:31
GlobeNewswire

CRISPR Therapeutics presents Phase 1a CTX310 data at ESC Congress 2026

CRISPR Therapeutics presented Phase 1a data for CTX310, its in vivo ANGPTL3 gene-editing candidate, at ESC Congress 2026. The company describes deep and durable ANGPTL3 editing with triglyceride and LDL lowering. Specific percentage reductions are in the release but are not restated here.

大盘 打开原文 ↗

监管

14:26
CNBC

FDA approves Gilead daily HIV pill designed to simplify treatment

The FDA approved a once-daily HIV pill from Gilead Sciences intended to simplify treatment for some patients, per CNBC. No trial or pricing figures are reproduced here beyond what the headline states.

大盘 打开原文 ↗

合作

12:00
Defense News

Air Force awards Boeing $131 billion ceiling contract for F-15 production, modernization

The U.S. Air Force awarded Boeing the sole-source "F-15 Eagle Crest" indefinite-delivery/indefinite-quantity contract on 24 August, capping at $131.23 billion what it may order through 2031 (extendable to 2036) for F-15 production, systems integration, modernization, retrofits, sustainment and organic depot maintenance, for the Air Force, Air National Guard and foreign buyers. The ceiling is not a commitment: only $343,740 in fiscal 2026 RDT&E funds was obligated at award.

大盘 打开原文 ↗

合作

10:17
GlobeNewswire

Teva announces proposed acquisition of a novel neuroscience product

Teva announced a proposed acquisition of a novel neuroscience product under its Pivot to Growth strategy. A same-day release from BioXcel Therapeutics announcing an asset sale agreement with Teva Pharmaceuticals identifies the counterparty. Deal terms are not stated in the headline and are not reproduced here.

大盘 打开原文 ↗

原始消息流

所有到达的消息 · 7 天